NervGen Enterprise Value Over E B I T D A from 2010 to 2024
| NGEN Stock | CAD 2.79 0.01 0.36% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (8.39) | Current Value (8.81) | Quarterly Volatility 2.1 K |
Check NervGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NervGen Pharma's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 4.9 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NervGen financial statements analysis is a perfect complement when working with NervGen Pharma Valuation or Volatility modules.
NervGen | Enterprise Value Over E B I T D A |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.